Acarbose treatment of type 2 diabetes mellitus.docVIP

 PAGE \* MERGEFORMAT 5 Acarbose treatment of type 2 diabetes mellitus [Keywords:] acarbose clinical analysis of type 2 diabetes mellitus Past 3 years, we applied acarbose (acarbose) and Jun LIDA (metformin) in the treatment of type 2 diabetes, 50 patients were compared. Basically the same rate of improvement of clinical symptoms, lowering blood sugar: acarbose group reduced meals Jun force after more than 2h of blood glucose group, lower fasting blood glucose less than Jun force of group. Observation of the two drugs reported as follows. 1 Materials and Methods 1.1 General Information The subjects were in accordance with the 1985 World Health Organization standard patient diagnosed with type 2 diabetes, were confirmed by more than 4 weeks of diet control not satisfied, fasting plasma glucosegt; 7.8mmol / L, postprandial 2h plasma glucosegt; 11.1mmol / L, 51 M patients, 49 females, aged 40 to 67 years, duration of 1 month to 2 years. to these patients, 50 patients were randomly divided into two groups, one group of acarbose treatment group, another group of King and force of the treatment group , There were no complications of diabetes. two groups of age, sex and no significant difference in blood sugar, comparable. 1.2 Methods 1.2.1 Treatment Diet and drug therapy at the same time. The amount and structure of the two groups the same diet. Acarbose group, oral Bayer Healthcare Co., Ltd. Beijing, China, the production of acarbose, an initial dose of 50mg, 3 times a day, 1 month no significant improvements after the glucose dose increased to 100mg, 3 times a day. Jun power of group, oral Beijing Pharmaceutical Co., Ltd. of St John Jun force of production, the initial dose of 0.25g, 3 times a day .1 months no significant improvements after the glucose dose increased to 0.5g, 3 times a day. 1.2.2 Observation method Before treatment and 1 month after the record symptoms, signs, fasting and 2h postprandial blood glucose (oxidase method),